Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study to Evaluate the Effectiveness and Safety of Ipilimumab, Administered During the European Expanded Access Programme in Pretreated Patients With Advanced (Unresectable or Metastatic) Melanoma

NCT02492815 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT02492815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02492815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study to Evaluate the Effectiveness and Safety of Ipilimumab, Administered During the European Expanded Access Programme in Pretreated Patients With Advanced (Unresectable or Metastatic) Melanoma
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Completed
Start date
October 31, 2013
Completion date
April 30, 2016
Enrollment
1,773 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma